Priority Review in Merkel Cell Carcinoma, Breakthrough Designation in RET-Altered Cancers, and More

2 意见
administrator
administrator
07/17/23

Gina Columbus reports on a priority review designation in Merkel cell carcinoma, a breakthrough therapy designation in select RET-altered cancers, an application submitted in pediatric ALL, and European approvals in multiple myeloma, melanoma, and ALL.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个